机译:乳腺癌分子生物标志物发现的新趋势
Laboratory for Prenatal Medicine and Gynecologic Oncology, Women's Hospital/Department of Biomedidne, University of Basel, Basel,Switzerland;
Laboratory for Prenatal Medicine and Gynecologic Oncology, Women's Hospital/Department of Biomedidne, University of Basel, Basel,Switzerland;
Laboratory for Prenatal Medicine and Gynecologic Oncology, Women's Hospital/Department of Biomedidne, University of Basel, Basel,Switzerland;
University Medical Center Freiburg, Freiburg, Germany;
Laboratory for Prenatal Medicine and Gynecologic Oncology Women's Hospital /Department of Biomedicine University of Basel Hebelstrasse 20, Room Nr. 416 Basel CH 4031 Switzerland;
机译:乳腺癌疾病特异性阵列(DSA)–从乳腺癌衍生的FFPE组织中发现生物标志物的平台
机译:乳腺癌疾病特异性阵列(DSA)–从乳腺癌衍生的FFPE组织中发现生物标志物的平台
机译:大肠癌分子和细胞生物标志物发现的新趋势
机译:CHR8Q24发现卵巢癌生物标志物的甲基化,拷贝数和LOH分析
机译:使用5-氟尿嘧啶和相关生物标记物的个性化乳腺癌管理:分子生物学和商业角度
机译:大肠癌分子和细胞生物标志物发现的新趋势
机译:分子改变和Poziotinib疗效,一种泛抑制剂,在人表皮生长因子受体2(HER2) - 阳性乳腺癌中:来自Poziotinib的II期临床试验的探索性生物标志物分析,用于难治性HER2阳性乳腺癌患者
机译:新型分子成像剂检测转移性乳腺癌的生物标志物